ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Veru, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action– VERU
19 déc. 2022 11h35 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and...
爱科百发宣布呼吸道合胞病毒新药爱司韦®的上市许可申请获国家药品监督管理局正式受理并纳入优先审评审批程序
08 déc. 2022 20h00 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中国上海, Dec. 09, 2022 (GLOBE NEWSWIRE) -- 上海爱科百发生物医药技术股份有限公司（以下简称“ 爱科百发”），一家致力于儿科及呼吸疾病领域创新药研发的生物制药企业，今日宣布中国国家药品监督管理局正式受理治疗呼吸道合胞病毒（RSV）感染新药爱司韦®（通用名：齐瑞索韦/ziresovir）的上市许可申请（NDA），并且纳入“优先审评审批”程序。 ...
愛科百發宣佈呼吸道合胞病毒新藥愛司韋®的上市許可申請獲國家藥品監督管理局正式受理並納入優先審評審批程式
08 déc. 2022 20h00 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
中國上海, Dec. 09, 2022 (GLOBE NEWSWIRE) -- 上海愛科百發生物醫藥技術股份有限公司（以下簡稱“ 愛科百發”），一家致力於兒科及呼吸疾病領域創新藥研發的生物製藥企業，今日宣佈中國國家藥品監督管理局正式受理治療呼吸道合胞病毒（RSV）感染新藥愛司韋®（通用名：齊瑞索韋/ziresovir）的上市許可申請（NDA），並且納入“優先審評審批”程式。 ...
Ark Biopharmaceutical Announces NMPA Acceptance and Priority Review of New Drug Application for Ziresovir for Treatment of RSV Infection
08 déc. 2022 20h00 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical), a biopharma company dedicated to the discovery and development of drugs for...
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
06 oct. 2022 07h00 HE
|
Entera Bio Ltd.
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
29 sept. 2022 07h28 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages World Wrestling Entertainment, Inc. Investors to Inquire About Securities Class Action Investigation – WWE
21 juin 2022 15h00 HE
|
The Rosen Law Firm PA
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of World...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
05 juin 2022 17h15 HE
|
The Rosen Law Firm PA
NEW YORK, June 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
20 mai 2022 13h53 HE
|
The Rosen Law Firm PA
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Axsome...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action – FENC
02 avr. 2022 15h00 HE
|
The Rosen Law Firm PA
NEW YORK, April 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May...